Gastroenterology
Volume 125, Issue 2 , Pages 413-420, August 2003

Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine

  • Tor C Savidge

      Affiliations

    • Corresponding Author InformationAddress requests for reprints to: Tor C. Savidge, Ph.D., Developmental Gastroenterology Laboratory, Combined Program in Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital and Harvard Medical School, 114 16th Street, Charlestown, Massachusetts 02129, USA; fax: (617) 726-4172
    • Laboratory of Developmental Gastroenterology, Combined Department of Pediatric Gastroenterology & Nutrition, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA
  • ,
  • Wei-hua Pan

      Affiliations

    • Laboratory of Developmental Gastroenterology, Combined Department of Pediatric Gastroenterology & Nutrition, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA
  • ,
  • Paul Newman

      Affiliations

    • Laboratory of Developmental Gastroenterology, Combined Department of Pediatric Gastroenterology & Nutrition, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA
  • ,
  • Michael O’Brien

      Affiliations

    • Department of Anatomic Pathology, Boston University School of Medicine, Boston, Massachusetts, USA
  • ,
  • Pauline M Anton

      Affiliations

    • Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
  • ,
  • Charalabos Pothoulakis

      Affiliations

    • Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

Received 31 July 2002; accepted 8 May 2003.

Abstract 

Background & aims:

Clostridium difficile causes antibiotic-associated diarrhea and pseudomembranous colitis, diseases afflicting millions of people each year. Although C. difficile releases 2 structurally similar exotoxins, toxin A and toxin B, animal experiments suggest that only toxin A mediates diarrhea and enterocolitis. However, toxin A-negative/toxin B-positive strains of C. difficile recently were isolated from patients with antibiotic-associated diarrhea and colitis, indicating that toxin B also may be pathogenic in humans.

Methods:

Here we used subcutaneously transplanted human intestinal xenografts in immunodeficient mice to generate a chimeric animal model for C. difficile toxin-induced pathology of human intestine.

Results:

We found that intraluminal toxin B, like equivalent concentrations of toxin A, induced intestinal epithelial cell damage, increased mucosal permeability, stimulated interleukin (IL)-8 synthesis, and caused an acute inflammatory response characterized by neutrophil recruitment and tissue damage. Laser capture microdissection and real-time quantitative reverse-transcription polymerase chain reaction (RT-PCR) showed that intestinal epithelial cell-specific IL-8 gene expression also was increased significantly after luminal exposure to C. difficile toxins in vivo.

Conclusions:

We conclude that C. difficile toxin B, like toxin A, is a potent inflammatory enterotoxin for human intestine. Future therapeutic or vaccine strategies for C. difficile infection therefore need to target both toxins.

Abbreviations:  GAPDH, glyceraldehyde-3-phosphate dehydrogenase, IEC, intestinal epithelial cell, IL, interleukin, RT-PCR, reverse-transcription polymerase chain reaction

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by the Crohn’s and Colitis Foundation, and the National Institutes of Health (DK33506; DK40561).

PII: S0016-5085(03)00902-8

doi:10.1016/S0016-5085(03)00902-8

Gastroenterology
Volume 125, Issue 2 , Pages 413-420, August 2003